Zimmer B, Kant R, Zeiler D, Brilmyer M
Allegheny General Hospital, Department of Psychiatry, Pittsburgh, PA 15212-5234, USA.
Int J Psychiatry Med. 1997;27(4):353-64. doi: 10.2190/UDRD-99CB-T6KH-EDKP.
To determine whether venlafaxine exerts a differential effect on blood pressure in young versus old depressed patients.
We compared thirty-four consecutive patients treated with 50-250 mg/day venlafaxine for major depressive disorder or another major mood disorder at our medical college's ambulatory neuropsychiatry program. We obtained baseline and follow-up blood pressure measurements. Each patient also received a baseline and final Clinical Global Impressions (CGI) score; global improvement was determined by consensus of two clinicians.
Sixteen nongeriatric patients (age, 13 to 56 years) were compared with eighteen elderly patients (age, 65 to 86 years). Most patients (88%) had serious medical comorbidities or histories. Despite a higher mean daily venlafaxine dosage for patients in the young group, no significant changes in systolic blood pressure were noted in either group. For the older group, we found a non-statistically significant 4.7 mm Hg mean increase in diastolic blood pressure. No patient became hypertensive. We also found a negative correlation between baseline diastolic blood pressure and change in diastolic blood pressure during treatment with venlafaxine. This inverse relationship was statistically significant in the older patients.
Venlafaxine was not associated with significant, sustained changes in blood pressure in any patient receiving dosages of 50-250 mg/day. Minimal changes in diastolic blood pressure were no more likely to occur in older venlafaxine-treated patients than in younger ones. Higher baseline diastolic blood pressure in older patients, but not in younger ones, seemed to protect against diastolic adrenergic blood pressure effects of venlafaxine.
确定文拉法辛对年轻与老年抑郁症患者的血压是否有不同影响。
我们比较了在我院门诊神经精神病项目中连续接受50 - 250毫克/日文拉法辛治疗的34例重度抑郁症或其他重度心境障碍患者。我们获取了基线和随访时的血压测量值。每位患者还接受了基线和最终的临床总体印象(CGI)评分;总体改善情况由两名临床医生共同确定。
16例非老年患者(年龄13至56岁)与18例老年患者(年龄65至86岁)进行了比较。大多数患者(88%)有严重的内科合并症或病史。尽管年轻组患者的文拉法辛日均剂量较高,但两组的收缩压均未出现显著变化。对于老年组,我们发现舒张压平均升高4.7毫米汞柱,但无统计学意义。没有患者出现高血压。我们还发现基线舒张压与文拉法辛治疗期间舒张压变化之间存在负相关。这种反向关系在老年患者中具有统计学意义。
在任何接受50 - 250毫克/日剂量文拉法辛治疗的患者中,文拉法辛与血压的显著、持续变化无关。接受文拉法辛治疗的老年患者舒张压的微小变化并不比年轻患者更常见。老年患者而非年轻患者较高的基线舒张压似乎可预防文拉法辛对舒张压的肾上腺素能血压效应。